Jordi Remón

10.1k total citations · 2 hit papers
175 papers, 3.7k citations indexed

About

Jordi Remón is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Jordi Remón has authored 175 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Pulmonary and Respiratory Medicine, 110 papers in Oncology and 46 papers in Cancer Research. Recurrent topics in Jordi Remón's work include Lung Cancer Treatments and Mutations (117 papers), Lung Cancer Research Studies (52 papers) and Cancer Immunotherapy and Biomarkers (51 papers). Jordi Remón is often cited by papers focused on Lung Cancer Treatments and Mutations (117 papers), Lung Cancer Research Studies (52 papers) and Cancer Immunotherapy and Biomarkers (51 papers). Jordi Remón collaborates with scholars based in France, Spain and United States. Jordi Remón's co-authors include Benjamin Besse, Noemı́ Reguart, David Planchard, Lizza Hendriks, Enriqueta Felip, Suresh S. Ramalingam, Conor Steuer, Jean‐Charles Soria, P. Lianes and Margarita Majem and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Jordi Remón

168 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Non-small-cell lung cancer

2024 127 citations Lizza Hendriks, Jordi Remón et al. profile →
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

2023 105 citations Jordi Remón, Lizza Hendriks et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jordi Remón France	34	2.4k	2.1k	1.0k	977	274	175	3.7k
Ernest Nadal Spain	34	1.8k 0.8×	1.8k 0.8×	1.5k 1.5×	815 0.8×	228 0.8×	169	3.6k
Christina S. Baik United States	27	1.8k 0.8×	2.1k 1.0×	1.3k 1.3×	685 0.7×	403 1.5×	116	3.5k
Hiroaki Akamatsu Japan	28	3.8k 1.6×	3.5k 1.6×	1.2k 1.2×	1.1k 1.1×	228 0.8×	144	5.1k
Biagio Ricciuti United States	33	1.7k 0.7×	2.6k 1.2×	1.1k 1.0×	774 0.8×	265 1.0×	161	3.8k
Xue Wu China	31	1.7k 0.7×	1.8k 0.8×	1.2k 1.2×	1.3k 1.4×	526 1.9×	163	3.4k
Anh T. Le United States	20	2.3k 1.0×	2.1k 1.0×	1.4k 1.4×	869 0.9×	491 1.8×	56	3.5k
Mario Giuliano Italy	34	1.2k 0.5×	2.4k 1.1×	1.0k 1.0×	1.4k 1.4×	239 0.9×	109	3.8k
Hidetoshi Hayashi Japan	36	2.8k 1.2×	3.7k 1.7×	1.4k 1.4×	705 0.7×	394 1.4×	248	5.2k
Joo Hang Kim South Korea	27	1.9k 0.8×	1.9k 0.9×	789 0.8×	426 0.4×	225 0.8×	91	3.0k
Enric Carcereny Spain	26	1.6k 0.7×	1.9k 0.9×	856 0.8×	515 0.5×	207 0.8×	183	2.9k

Countries citing papers authored by Jordi Remón

Since Specialization

Citations

This map shows the geographic impact of Jordi Remón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jordi Remón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jordi Remón more than expected).

Fields of papers citing papers by Jordi Remón

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jordi Remón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jordi Remón. The network helps show where Jordi Remón may publish in the future.

Co-authorship network of co-authors of Jordi Remón

This figure shows the co-authorship network connecting the top 25 collaborators of Jordi Remón. A scholar is included among the top collaborators of Jordi Remón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jordi Remón. Jordi Remón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Remón, Jordi, Paolo Bironzo, Nicolas Girard, et al.. (2025). Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. The Lancet Oncology. 26(9). 1215–1226. 1 indexed citations

Arrieta, Óscar, Luis Lara‐Mejía, Andrés F. Cardona, et al.. (2025). Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial. Nature Communications. 16(1). 4553–4553. 2 indexed citations

Tagliamento, Marco, David Planchard, Fabrice Barlési, et al.. (2024). Brief Report: Targeted Therapies and Pancreatitis in Patients With Advanced Nonsmall Cell Lung Cancer. Clinical Lung Cancer. 25(8). e482–e486.e3.

Saw, Stephanie P.L., Xiuning Le, Lizza Hendriks, & Jordi Remón. (2024). New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors. American Society of Clinical Oncology Educational Book. 44(3). e432516–e432516. 5 indexed citations

Uprety, Dipesh, Jordi Remón, & Solange Peters. (2023). First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non–Small-Cell Lung Cancer: Are We Ready to Use It?. Journal of Clinical Oncology. 42(4). 378–382. 5 indexed citations

Tagliamento, Marco, Massimo Di Maïo, Jordi Remón, et al.. (2023). Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma. Journal of Thoracic Oncology. 19(1). 166–172. 8 indexed citations

Houda, Ilias, Idris Bahce, Chris Dickhoff, et al.. (2023). OA06.03 An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 18(11). S55–S56. 8 indexed citations

Riudavets, Mariona, Damien Vasseur, Édouard Auclin, et al.. (2022). Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer. Clinical Lung Cancer. 23(6). e377–e383. 1 indexed citations

Tagliamento, Marco, Jordi Remón, Matteo Giaj Levra, et al.. (2022). Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey. JTO Clinical and Research Reports. 4(1). 100446–100446. 3 indexed citations

10.

Faugeroux, Vincent, Marianne Oulhen, Olivier Déas, et al.. (2022). Targeting genome integrity dysfunctions impedes metastatic potency in non–small cell lung cancer circulating tumor cell–derived explants. JCI Insight. 7(11). 10 indexed citations

11.

Remón, Jordi, Nicolas Girard, Silvia Novello, et al.. (2021). PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clinical Lung Cancer. 23(3). e243–e246. 24 indexed citations

12.

Ruysscher, Dirk K.M. De, et al.. (2021). Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review. Critical Reviews in Oncology/Hematology. 166. 103460–103460. 6 indexed citations

13.

Remón, Jordi & Gilberto Lopes. (2020). Upfront osimertinib — winner takes it all?. Nature Reviews Clinical Oncology. 17(4). 202–203. 7 indexed citations

14.

Remón, Jordi, et al.. (2020). <p>Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context</p>. OncoTargets and Therapy. Volume 13. 6885–6896. 2 indexed citations

15.

Benítez, José Carlos, Jordi Remón, & Benjamin Besse. (2020). Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy. Clinical Cancer Research. 26(19). 5068–5077. 40 indexed citations

16.

Pailler, Emma, Vincent Faugeroux, Marianne Oulhen, et al.. (2019). Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK -Rearranged Non–Small-Cell Lung Cancer. Clinical Cancer Research. 25(22). 6671–6682. 92 indexed citations

17.

Remón, Jordi, et al.. (2018). Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. Cancer Treatment Reviews. 71. 47–58. 37 indexed citations

18.

Pailler, Emma, Marianne Oulhen, Isabelle Borget, et al.. (2017). Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK -Rearranged Non–Small Cell Lung Cancer Patients. Cancer Research. 77(9). 2222–2230. 59 indexed citations

19.

Facchinetti, Francesco, Yohann Loriot, Mei-Shiue Kuo, et al.. (2016). Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1 - and ALK -Rearranged Lung Cancers. Clinical Cancer Research. 22(24). 5983–5991. 111 indexed citations

20.

Remón, Jordi, et al.. (2014). Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies. Cancer Treatment Reviews. 41(1). 27–34. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact